PADDING
UNK
,
of
the
.
and
in
)
(
with
to
a
:
patients
that
for
gene
by
was
is
*
on
=
were
/
The
or
polymorphisms
as
-
polymorphism
expression
cancer
not
associated
treatment
an
In
response
genotype
be
study
1
P
%
are
;
receptor
between
alcohol
cells
3
mutation
cell
We
association
2
EGFR
we
may
but
levels
therapy
activity
significantly
treated
after
have
A
effects
from
+
this
which
clinical
inhibitor
CYP3A5
genetic
allele
mice
-induced
at
chemotherapy
mutations
risk
than
significant
dependence
dose
<
increased
effect
results
these
kinase
CONCLUSIONS
role
found
compared
higher
human
has
protein
also
p
resistance
promoter
RESULTS
p53
group
breast
among
who
genotypes
CYP2C19
n
CONCLUSION
genes
did
variants
showed
increase
combination
reduced
To
warfarin
tacrolimus
CYP2D6
-based
subjects
studies
CYP2C9
C
survival
mutant
had
METHODS
suggest
wild-type
sensitivity
population
CYP3A4
plasma
status
This
efficacy
lower
Our
advanced
single
their
been
toxicity
drug
metabolism
HER2
lung
mRNA
factor
NSCLC
cocaine
both
growth
VKORC1
transporter
nucleotide
concentrations
carriers
plus
no
drugs
acid
administration
chronic
well
its
]
TPMT
SNP
more
use
model
other
influence
whether
inhibitors
activation
tumors
exon
[
induced
BACKGROUND
serotonin
one
alleles
SNPs
95
These
tumor
first
different
-dependent
against
P450
during
only
4
Chinese
HLA-B
ABCB1
cytochrome
nicotine
differences
MTHFR
present
dopamine
including
control
ratio
respectively
variability
type
vivo
COMT
10
while
two
controls
BRAF
development
show
related
colorectal
those
concentration
lines
examined
0
pharmacokinetics
high
observed
all
major
platinum
either
receiving
dependent
line
indicate
blood
functional
benefit
data
can
Japanese
serum
tamoxifen
CI
when
used
daily
function
clopidogrel
paclitaxel
KRAS
ribavirin
involved
within
women
into
such
previously
6
inhibition
irinotecan
using
vitro
investigated
-treated
decreased
analysis
common
oral
deficiency
apoptosis
presence
recipients
responses
heroin
demonstrated
-positive
evaluate
>
healthy
signaling
tyrosine
variant
findings
years
might
groups
II
alone
investigate
OBJECTIVE
metastatic
affect
potential
haplotype
hypersensitivity
Patients
erlotinib
induction
based
whereas
liver
demonstrate
reduction
Association
important
mean
hepatitis
MDR1
early
acute
age
low
changes
exposure
target
mg
5-HTTLPR
variation
dehydrogenase
greater
associations
agonist
pathway
transplant
first-line
homozygous
h
therapeutic
shown
deletion
identified
without
could
following
doses
predictive
'
assessed
overall
novel
predictor
hepatic
ethanol
thiopurine
test
suggesting
analyzed
aspirin
through
5
known
MTX
5-FU
renal
region
number
combined
manner
B
adverse
AND
conclusion
studied
determine
S
susceptibility
carrying
5701
I
0.001
melanoma
12
clearance
T
further
disease
reductase
trial
0.05
cancers
DNA
epidermal
However
neurons
abacavir
-mediated
maintenance
cases
contrast
agents
standard
inhibited
phase
genotyping
OR
level
Nrf2
enzyme
outcomes
it
expressed
pharmacokinetic
frequency
-related
our
synthase
imatinib
lansoprazole
effective
interindividual
virus
rat
increases
enzymes
under
do
Using
aim
CpG
coronary
reported
abuse
four
measured
UGT1A1
proliferation
metabolic
leukemia
estrogen
8
progression-free
CC
impact
IL28B
useful
area
5-fluorouracil
activated
Although
c-fos
-mutant
azathioprine
rates
sensitive
No
domain
interaction
rate
patient
cellular
CYP2A6
kidney
syndrome
encoding
odds
AUC
behavioral
value
hypothesis
brain
cohort
regimen
smoking
via
specific
screening
followed
relation
disposition
methamphetamine
better
channel
glucose
men
metabolizers
nitric
oxide
less
death
time
molecular
detected
poor
's
contribute
doxorubicin
genotyped
appears
vitamin
normal
beta
addiction
anti-
vs.
haplotypes
affected
relationship
methylation
9
induces
cholesterol
considered
subunit
Val
There
carcinoma
play
CBZ
events
7
review
PIK3CA
ITPA
influenced
system
because
anthracycline
ratios
lithium
cetuximab
assess
It
required
difference
testing
PURPOSE
evaluated
oxaliplatin
Moreover
regulatory
ovarian
seen
highly
DRD2
driven
risperidone
expressing
assay
African
docetaxel
factors
support
populations
single-nucleotide
reduces
individuals
similar
adjuvant
concentration-time
inhibiting
outcome
GABRA2
potent
affects
cyclophosphamide
trastuzumab
parameters
current
multiple
C3435T
primary
binding
receptors
revealed
arsenic
sustained
Phase
nucleus
0.03
developed
and/or
"
CYP4F2
body
ABCG2
platelet
if
addition
per
change
disorders
Here
5-HTT
interactions
received
confidence
schizophrenia
Cancer
regression
determined
suggested
locally
prior
peginterferon
occurrence
additional
evidence
SLCO1B1
individual
accumulation
extracellular
likely
C677T
mechanism
cyclosporine
SIRT1
harboring
pharmacodynamic
injection
non-small
relapse
adenosine
Genetic
baseline
days
included
strong
substitution
weight
ALK
clinically
BDNF
recently
cisplatin
predict
enhanced
least
SVR
some
tandem
antagonist
lipid
complex
anxiety
established
result
CYP2B6
40
prognostic
crizotinib
proteins
AD
transplantation
mg/kg
virological
CREB
indicating
infection
responsible
phosphorylation
possible
KIT
iron
ligand
correlated
BRCA1
tested
there
morphine
methotrexate
analyses
c-Fos
DPYD
interval
gefitinib
metabolites
One
CHC
Arg
endothelial
recurrence
seem
total
cardiac
weeks
mechanisms
respond
6-mercaptopurine
confer
lapatinib
11
same
profile
PFS
MET
DAT
Val158Met
28
glutathione
purpose
AR
estradiol
VNTR
injury
disorder
comparison
resistant
encoded
TEN
17
non-small-cell
curve
volunteers
prevalence
sorafenib
elimination
dose-dependent
HFE
pretreatment
ER
each
lead
small
depressive
toward
inhibits
microg
hypothesized
metabolized
prostate
angiotensin
When
exhibited
induce
reactions
1B
several
thymidylate
.0001
AIMS
vemurafenib
alpha
content
16
0.01
finding
distribution
r
ALL
although
N
male
asthma
Fos
thus
directed
damage
provided
phenotype
marker
interferon
part
ability
before
androgen
active
selection
sequencing
diabetes
drinking
however
gemcitabine
20
will
HIV-1
Therefore
depletion
1G
persistent
SJS
ADH1B
opioid
models
stable
improved
trend
TNF-alpha
reward
any
particularly
due
selected
caused
large
Polymorphisms
urinary
i.e.
diet
celecoxib
requirements
responded
haloperidol
enhances
transcriptional
extensive
previous
coding
GSTP1
stage
showing
severe
-mutated
knockout
COX-2
direct
ERCC1
versus
-resistant
ERK1/2
ATM
constitutive
elevated
targets
given
tolerance
.02
probe
muscle
lipase
EPHX1
Mutations
suicide
preclinical
nuclear
secondary
statins
Resistance
promising
hydroxylase
treatments
variable
release
epoxide
degree
rt
fentanyl
fact
glutamate
predicts
metabolizing
MDR-1
27
III
HLA-C
GSTM1
mesylate
cAMP
provides
HLA-A
receive
DESIGN
self-administration
MLL
report
safety
independent
carrier
c-myc
hormone
point
regions
order
abnormalities
insulin
Effects
-specific
indicated
include
reverse
radiation
Among
regardless
pattern
antigen
profiles
action
CYP2C8
achieve
Furthermore
agent
50
ng
triglyceride
vascular
mouse
hematopoietic
capacity
metformin
history
ADH2
oncogene
predicting
ARE
t
prevented
recent
clear
rs9923231
Z
atherosclerosis
promoted
ACE
D
RBV
toxic
CFTR
striatal
where
activities
Pharmacogenetics
decrease
tumour
possibly
plants
Since
After
even
most
substrate
S-methyltransferase
preference
polymorphic
lesions
aggressive
nelfinavir
L
myelosuppression
three
dyskinesia
TT
heterozygotes
epithelial
lack
pharmacological
HO-1
b
subset
G
2A
membrane
neoadjuvant
explore
shows
75
towards
calcium
CYP
characteristics
thrombosis
homozygotes
positive
European
hepatocellular
GSTT1
work
continued
pharmacogenetic
unresectable
affecting
FLT3
randomized
phenotypes
inhibit
orally
histone
Caucasian
adult
homocysteine
abnormal
non-
Breast
hydroxylation
P-gp
CYP3A
rs9934438
vs
rs2108622
authors
PEG-IFN
CD4
improve
targeted
correlation
diminished
case
Group
performance
arrest
Korean
childhood
nor
place
correlate
influences
day
strongly
R
carried
performed
months
essential
approach
does
pancreatic
alterations
located
24
Effect
secretion
member
isolates
favorable
constructs
impaired
JAK2
uptake
carboplatin
MCL
inosine
formation
capecitabine
index
tissue
alter
p21
determinants
relevant
colon
domains
endogenous
adjusted
appear
organic
five
Lung
TKIs
dosage
year
American
should
involvement
Cyclin
pathways
AZA
viral
chemotherapeutic
MEK1/2
A118G
tissues
plasmid
poorer
intraperitoneal
APAP
isoform
adrenergic
primarily
pharmacodynamics
15:02
XRCC1
examine
frequencies
whose
mCRC
family
placebo
myeloid
checkpoint
150
intronic
setting
modest
transferrin
CYP1A1
HIV
restored
NAT2
14
M184V
losartan
L858R
modulate
digoxin
withdrawal
lipoprotein
cytogenetic
PPARalpha
iNOS
percutaneous
extent
70
subfamily
plays
pfmdr1
L90M
heterozygous
Molecular
61
dystonia
21
biosynthesis
gastric
extracted
MMA
corresponding
nicotinic
Polymorphism
CD8
cassette
MK
PR
RFS
subgroup
stent
thereby
everolimus
produced
loss
molecules
pressure
triphosphate
30
Caucasians
negatively
develop
myelogenous
Japan
memory
dexamethasone
decreases
classes
female
c.
exposed
yet
pharmacogenetics
ADV
reactivated
minor
PSA
according
genetically
0.06
replaced
striatum
antiplatelet
phenotyping
contributed
codeine
SLC6A4
NMDA
TOP2A
especially
Sp1
synthetic
200
sample
avoid
For
nasal
inducing
Is
WT
protective
overexpression
MMP-2
they
tryptophan
60
RFC1
sirolimus
much
K
antiretroviral
failed
01
psychosis
symptoms
D1
15
EGCG
kinetics
Depression
Accordingly
identifying
cADRs
lysine
larger
regulate
immunity
dose-adjusted
immediate
selective
antitumor
XIAP
D4
out
behavior
c-
hours
HCV
homologous
ALDH2
properties
descent
hippocampal
oocytes
GABA
mitochondrial
month
mg/m
MDR
dabrafenib
-associated
fludarabine
TYMS
IDH1
markedly
?
start
partial
mitotic
protect
/neu
down-regulates
catechol-O-methyltransferase
PATIENTS
-TKI
harbored
differentiation
rs1057910
inositol
ADRB2
acenocoumarol
Additionally
antibody
Tamoxifen
marked
Hsp90
diabetic
linear
GCV
TS
-expressing
multidrug
PEG
predominantly
Inhibitor
basis
downstream
74
100
size
duplication
Bcl-2
NF-kappaB
On
murine
OS
investigation
smoke
Val66Met
dynamics
regulates
enhancement
OBJECTIVES
Treatment
CDA
infusion
Cyp51
second
chloride
preoperative
paroxetine
PDYN
certain
TNF
transfer
HR
phenylalanine
approved
reporter
require
distinct
inhibitory
carbamazepine
3A4
missense
clozapine
substrates
translocation
-5
consistent
central
new
Na(+)
transcriptase
follow-up
TK
injections
0.02
twice
R-
grade
CHFR
negative
pilot
26
bone
Ras
Maintenance
immunization
administered
altered
variations
At
250
containing
mutants
PTH
acetylcholine
cytotoxicity
-targeted
doublet
alcoholism
experimental
TNBC
respect
Hb
bevacizumab
t.i.d.
transferase
low-dose
aimed
laboratory
13
HLA-
loss-of-function
correlates
virologic
transcription
pegylated
MGMT
open-label
efavirenz
V600E
LSZ
lowering
C/D
greatly
trials
dihydropyrimidine
invasion
signs
focused
mediated
reaction
seems
so
Transplant
allopurinol
PACAP
having
probably
norepinephrine
suggests
5-HT
GGCX
carry
sex
like
Sorafenib
52
C/T
postmenopausal
rs8099917
upstream
DA
CCK
PPI
Tacrolimus
week
them
pain
MEK
CYP2A5
radiotherapy
would
modulates
dosing
absorption
LDL
-overexpressing
refractory
humans
determining
lymphoma
EXPERIMENTAL
together
UNASSIGNED
antidepressant
steroid
then
provide
peptide
lamivudine
inducible
meta-analysis
AA
Met
highest
Previous
Based
Vemurafenib
Epidermal
surface
OPRM1
PD
An
rise
HBV
Thus
stress
rechallenge
B1
nevirapine
phosphorylated
0.26
noncarriers
specificity
TLR9
MDS
cycle
deaminase
molecule
up-regulated
Lack
peak
ODN
males
six
initial
sensitization
kinases
P50
NPY
-tolerant
mellitus
antiapoptotic
statistically
PXR
hepatotoxicity
DRD4
median
ABCC2
voriconazole
noted
Results
US
skin
-negative
values
extract
Americans
hemoglobin
amphetamine
worse
folate
.04
prospectively
designed
identification
hypermethylation
suppression
upregulated
incidence
CYP2E1
methylenetetrahydrofolate
sulphonylureas
particular
3101
failure
improves
K-ras
UGT1A9
understanding
25
undergoing
-binding
suppressed
17-AAG
Also
find
solid
improvement
series
malignant
tumours
craving
P-glycoprotein
RIP3
4-HNE
exhibit
h/mL/mg
headache
58:01
icotinib
Conversely
excellent
From
chromosome
areas
cytosolic
segments
adrenal
CYP1B1
DRD3
safe
None
conversion
RRM1
anaplastic
hypothesize
caspase-3
MPA
prevention
pridopidine
weekly
S-transferase
post-
-regulated
dramatic
approximately
experiments
6-hydroxydopamine
pyrophosphatase
inflammation
rejection
express
-sensitive
repeat
limit
Combination
RY10-4
mitomycin
families
potently
activates
S-mephenytoin
systematic
side
hazard
C0
Asian
77
led
Ser49Gly
applied
abolishes
streptozotocin
life
Th2
ENO2
blockade
-TKIs
MLKL
sodium
rs6465084
Specifically
c-Jun
CXCL8
beneficial
metoprolol
adjustment
times
8-OHdG
familial
invasive
Oral
More
aged
0.04
immunohistochemistry
DGF
TD
skipping
CAT
cortical
N-methyl
hK2
fibroblast
cytarabine
xeroderma
once
extinction
While
/day
conferring
neo-adjuvant
Genomic
exacerbated
500
microinjection
fibrosis
chromatin
suppressor
azacitidine
60.7
ErbB-2
cytotoxic
species
published
carvedilol
mutated
progenitor
non-SVR
Q151M
zidovudine
luciferase
Phe
-deficient
irradiation
quantify
indicative
BCR-ABL
separate
natural
implying
CHRNA4
treat
staining
fluorescence
_
MM
Ins/Del
complete
.005
VCAM-1
simple
OCT2
treatment-naive
upon
vaccine
fluorouracil
neu
-1438A/G
abolished
partly
predictors
Study
CQ
Carriers
DD
IMO
DISCUSSION
patterns
x
psychological
A/G
Regulation
catabolism
Cr(VI)
personality
availability
cigarette
codons
until
stem
6-BG
rs6265
address
eIF3a
collies
Indians
components
GNB3
hormonal
plasmids
Cdx4
introduced
substitutions
delayed
suspected
avoiding
Catechol-O-methyltransferase
TPH1
5-azacytidine
Jun
general
consequences
T1
FMO3
bleeding
1-(m-chlorophenyl)piperazine
5-HT(3A
JAK3
attempts
DHPG
NNK
investigating
separation
H
modifications
Bax
medication
0.305
0.34
dextromethorphan
still
AZD6244
telaprevir
derived
explained
Pak1
NPHS2
expressers
SD
infinity
interest
resulting
h/mL
GSK-3
documented
immune
sunitinib
activate
BMD
high-dose
native
rs7294
immunosuppressive
resulted
5-MTHF
intrinsic
accounts
consequence
consisted
consolidation
metastases
non-drug
linked
able
encodes
supports
I3C
Han-Chinese
near
endometrial
scores
salbutamol
restenosis
sucrose
escalating
dopaminergic
creatinine
MAO-A
-containing
Identification
XPD
gadoxetic
Tat
harbouring
MCRC
geometric
biomarker
acutely
677C-->T
very
Taxol
intestinal
Studies
possibility
17-OH
loading
antagonists
MATERIAL
curves
0.034
fat
efflux
achieving
systemic
225
regulated
RUNX1
stroke
periods
pravastatin
frequently
Neither
BRCA
mediate
UGT1A
AF4
corr
nephrotoxicity
rifampicin
Beta2
relevance
-like
glycogen
water
bispectral
bupropion
0.004-0
Potential
pregnane
Currently
LL
Han
anticancer
characterized
Tyrosine
caffeine
1502
equivalent
hippocampus
Dutch
defining
animals
antidepressants
DAPT
consisting
subsequently
Parkinson's
mu-opioid
Similarly
c.428G>A
1A1
underwent
Long-term
aldehyde
C-RAF
diagnosis
X
antiproliferative
C57BL/6
ER/
RET-PTC-1
now
overcomes
longer
acquired
anaemia
conditioning
conclude
alcoholic
C282Y
alanine
OPRK1
matrix
being
pooled
stratified
transformation
BSC
depression
concluded
MSI
recognized
C/C
Gefitinib
channels
abnl
preventing
MOH
despite
activator
glucuronide
progression
kg
T315I
identify
METH
RAF
blocking
utility
cFos
Following
Indian
Ser9Gly
Single
accounted
concurrent
Dex
INH
HCC
Four
detect
evaluation
angiotensinogen
Human
anticoagulant
leads
Src
0-infinity
atorvastatin
critical
supplementation
Thai
insights
yield
chosen
adherent
talinolol
cation
repaglinide
smokers
intensity
CD
monoclonal
3435C>T
amiodarone
Impact
Cmax
GST
Influence
isoforms
inhaled
thymidine
dystrophin
MC
CAR
Bcr-Abl
reuptake
oxycodone
FDA
protocol
transporters
axial
pre-treatment
tobacco
confirm
Pi
attributable
Inhibition
dominant
naloxone
NPM1
DTNBP1
A218C
constructed
multikinase
Wt
Pcorr
affinity
(V600E
rs12979860
CRC
acetyltransferase
34
Cys
mixed
medulla
TAM
0-12
context
rapid
MUT
prognosis
leading
Common
M
rsGFP
cerebral
maternal
rare
AIM
summary
DOR-1
consumers
TNFalpha
interleukin
opening
myoclonus
cognitive
prescription
functions
DDP
cardiovascular
Warfarin
c.1236C>T
Findings
4.0
hematologic
apparently
efficiency
MnSOD
cytidine
thyroid
potentially
C>T
M1
mammary
Ile
transformed
AML1
intracellular
schizophrenic
1.5
0.007
cutaneous
interacts
supported
block
SERT
sequence
TAC
pivotal
modulator
proliferator-activated
occurring
reversed
mg/kg/day
combining
oncogenic
additive
oxidative
older
TKI-resistant
CYP1A2
tenofovir
MDRI
06:02
epirubicin
rs3213207
down-regulation
kappa
log-transformed
TNF-a
measures
techniques
ADRs
afatinib
indicates
DMA
Activating
6-MP
necrolysis
defects
p16INK4a
differ
white
co-trimoxazole
elevation
testosterone
discounted
E2
karyotype
terms
T>C
consecutively
ARM
myocardial
onset
high-
observations
H3
VEGF
child
decline
signal-regulated
3C
field
subsequent
borderline
45
phenotypic
maximum
influencing
absent
long-term
folic
overexpressing
supplement
WFS1
PCR
RET
objective
adjacent
fumigatus
Evidence
src
HT
increasing
ethnic
routine
regulation
systematically
POR
oseltamivir
describe
deficits
TCDD
reduce
rs2884737
23
ANKK1
ADH1C
hepatocytes
Kinase
1.1
SJW
propranolol
slices
implication
young
1A
tagging
ATP-binding
LAM
protection
artery
inorganic
.002
substance
severity
c.3435C>T
signal
explain
information
GH
correlations
mdr1a
SNPA
precipitated
prescribed
adequate
NQO1
strain
learning
sulfate
polyps
specifically
glial
sterol
microsomal
ve
average
V600K
peroxisome
VHL
0.1
BCL-2
chloramphenicol
phosphatidylinositol
attributed
obtained
PACT
relative
A2
heart
alcoholics
intervention
-selective
anticoagulation
-1
seeking
mutation-positive
stenting
NO
Hcy
pronounced
D-aspartate
acts
Another
mu
replicated
ALT
2D6
estimated
Acquired
P2Y12
E
nucleoside
glioma
19
users
venous
beta2-adrenergic
valproate
neurotoxicity
dysferlin
enhance
retinoic
ventral
prostaglandin
sequenced
presented
pleural
2C19
Drugs
NE
NADPH
ivermectin
Liver
anemia
excretion
-141
inferred
Nav1.5
1.37
mg/dL
progressive
antisense
salmeterol
GG
rats
incubated
propofol
basal
accumbens
importance
types
internal
repeated
amino-acid
Finnish
dyes
help
neither
CT
aspects
monotherapy
lectin
demethylase
q21
BEZ235
various
confirmed
Singapore
portion
recombination
p16
neurotransmitter
0.009
eNOS
Rhes
Sk-Ov-3
necessary
accompanied
aromatase
taxane
met
-terminal
Intracerebroventricular
already
cocktail
a2-subunit
H-ras
105
AERD
children
principal
Many
levodopa
cluster
c-jun
desensitization
VDR
44
Erlotinib
CDT
prediction
skeletal
2C9
makes
delay
contributes
0.5
hTERT
RT
activating
demonstrating
tomography
max
HLA-G
MDR2
S.
fertility
post-transplantation
concomitant
08:01
CES1
multicenter
remained
bile
enhancer
-eGFP
vinorelbine
therapies
controlled
ALDH1A1
null
pregnancy
density
final
rs776746
successfully
frequent
objectives
antioxidant
protects
neurotrophic
LTA
c-Met
EML4
TLR7
A2/A2
IFN-gamma
compounds
taxanes
72
sites
overload
CHRNA5
cortex
APOE
option
300
needed
postoperatively
TT/CC
shorter
escitalopram
DHFR
Age
markers
bioavailable
sleep
finger
98
heavy
polymerase
analogs
comparable
CsA
neuronal
glucocorticoid
TPN
all-trans
ADORA2A
HSP90
myeloma
functionally
positron
acetaminophen
Alcohol
attenuate
overuse
PDGFRA
48
systolic
analgesic
insertion/deletion
neuropathy
Polish
Stevens-Johnson
amplification
ventricular
IFN-alpha
females
pretreated
SNAG
emission
0.084
emtricitabine
eye
dramatically
1D
MEK1
glucokinase
Multiple
GO
tea
cyclooxygenase
immunoreactive
application
BCR/ABL
ng/mL/mg
production
ZNF
Both
mTOR
whole
HbA1c
challenge
cysteine
spontaneous
ESRD
irreversible
e.g.
0.0003
oxidase
D2
bortezomib
Pharmacogenomics
man
fraction
independently
orthologs
stages
endocrine
cultures
TP53
second-line
microM
RAS
pigmentosum
retrospectively
LFA-1
TKI
S-warfarin
midazolam
SSRI
tool
376
leukaemia
73
intravenous
cessation
delta
Recent
African-American
CBZ-epoxide
goal
flecainide
occur
p.Gly143Glu
screened
With
augmented
consumption
dehydroepiandrosterone
Growth
mild
effusions
PTGS2
debrisoquine
trait
candidate
DPD
immunogenicity
slow
prasugrel
myelodysplastic
/injury
NAc
deletions
CPT
reliably
2.24
BAG-1
endotoxin-associated
single-stage
1.46
sarcomatoid
MSNs
covariates
polyphenols
canine
questionnaire
vincristine
violence
P1655
i.p.-primed
likelihood
environmental
PSC
parasites
1.005
p-value
p-values
abusers
placement
ST
pmol/min/mg
19.95
embryo
0.031
robust
PKAI
EPT
stimuli
albeit
haemoglobin
Norepinephrine
-1175
co-mutation
waking
1826
resection
cold
mainly
FINDINGS
elucidate
15-keto-PGE2
delays
N265M
Kuwaiti
na
barely
benefits
debrizoquine
Niemann-Pick
HMG
A-alleles
Withdrawal-induced
chance
substitute
utilization
MT1A
four-drug
ferritin
GABAA
B-Cd
rs886003
Shh
ultrarapid
product
CaMKII
injected
617145
living-donor
immunodeficiency
numerous
potentiation
-45C>T
(V617F
CTX
French
dehydratase
FGF2
limited
Associations
3A
CPP
ApaI
ineffective
synaptic
symptomatic
Cytochrome
TULIP
4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline
Proguanil
biochemical
Ps
obese
respiratory
expiratory
EFV
alkylating
well-tolerated
Chronic
suitable
antimode
.The
18
Taiwanese
copper
202475-60-3
ATP
1.10
Analysing
delta-aminolevulinic
.0002
Jo2
mithramycin
process
14.18
fluorofentanyl
glycosylation
flux-based
phases
CNR1
co-morbidity
coumarin
considerable
HSD17B5
irinorecan
allografts
vaccination
Q56P
deoxycytidine
disulfide
incorporated
ERK1
metastasis-free
itself
vehicle-treated
individualised
Given
chromosomic
knockdown
consented
pretetanic
Tenofovir
LSZS
colonic
seizures
-Adrenergic
logistic
eriocalyxin
dideoxynucleoside
multi-
appearance
aggregation
Trial
GR
siRNA
Homer1
PDA
CYP450
y
c-abl
theories
representative
gastroesophageal
Recipients
cells/animal
PU.1
BO-653
addicts
2013
removed
cause
CES
-reactive
MPH
Aspergillus
duplications
cysteines
47.6
ABO
252
asked
MPAG
epilepsy
keratinocyte
participants
T286A
makers
G0103
loricrin
aminotransferase
bath
promoter-bound
Malaysian
Intriguingly
interfering
DAT1
peripheral
anxiolytic
0.430
PDAC
Preclinical
germline
G172T
IMPase
HCN1
descending
IPASS
line-derived
IFNL3
radiosensitization
DPYSL2
vector-mediated
simplex
V118I
prevents
androstenedione
Monitoring
transforming
p.R144C
UGT1A7
polyphosphate-1-phosphatase
fetuin-A
1.34-150
SK-OV-3
.007
v-raf
aflatoxin
339-345
unchanged
1V136
S/S
+14.4
NH2
meta-analytic
non-intoxications
Pompe
90
over-represented
fluoropyrimidines
monogenic
WCA
thrombotic
coagulation
I/R
nigra
cleaved
wall
XIII
sputum
Val34Leu
guarantee
fusion
confirms
HSV-
.35
stratification
BECN1
psychotic
mechanistic
rs2032582
reactivation
rs1934951
superior
azole
V617F
regimens
PlateletWorks
Smad3
-PDGFRalpha
front-line
mutagenicity
val66met
70-140
GP
Models
dorsalraphe
3.73
late-stage
D3
rs35597368
5-HT3AB
non-synonymous
Sensitization
Interestingly
reserve
anion
polypeptide
tanshinone
BAX
.1
magnesium
protease
Ala189Val
anastrozole
PLDIM5
GLUT2
mixture
17beta-estradiol
0.494
African-specific
181T
C0/D
expressors
35
acquire
acting
analyze
Efficacy
:10.1038
779A/C
rs448012
f
Akt
0.792
optimise
248
tablets
amyloid
non-interferon
DT-diaphorase
rs1799809
excision
existence
glycosylase
impressive
Management
beta1
human-2
expansion
311
163.6
FCER2
S65C
budesonide
analogues
28B
pERK1/2
bulk
resequenced
sexual
percent
SCH58500
fell
GIRK2
clotrimazole
AT1R
glioblastoma
synergistically
competence
2.91
normalized
OATP1B3
tapering
inferior
Taq
nortriptyline
XDH
AZD4619
CEL
temsirolimus
PNPLA3
86
DMXAA
0.025
-30G>A
2E1
IGF-1
NZB
socio-economically
-1.3
evoked
Q61
heme
circulating
hydroxyapatite
JANEX-1
topography
proinsulin
rs622342
thyroxine
OSCC
GIRK1
cigarettes
IL36RN
MEASURES
PD98059
cost-effectiveness
ABCC1
flashes
340
-R
GIST
deacetylase
hot
localization
GACI
rs1042713
VKORC
indinavir
1B1
Sulfotransferase
R408W
risks
TCPOBOP
.006
Reinfecting
B-cell
signalling
Ca2+
cyclosporin
hetero-monocyclic
RASSF1A
DNAs
Na
adolescents
silymarin
-prevalent
S-27609
HSV-TK/
thioguanine
atenolol
.24
alpha2C-AR
Arg389Gly
.049
immunoprecipitation
0.19-1
3T3
verapamil
CYP3A7
8.46
pulmonary
TIMP-2
probable
supersensitive
N-acetyl
derivatives
DBH
describes
matrine
Scale
evidenced
terbutaline
gatekeeper
hMOR
situ
circulatory
rituximab
external-beam
nalbuphine
Infection
drink
TGF-b1
SRs
Asn680Ser
usual
StAR
90-fold
APOA5
triphosphatase
Inventory-II
extra
feasible
networks
success
prostaglandins
misfolding
ritodrine
leptin
malignancies
G565A
PKA
mm
allozymes
estrogens
knock-down
HLSZ
Metoprolol
HER-2
0.3331
NK
Upfront
180.1
executive
microscopy
LDF
SSRIs
platelets
1.08-2
drastically
ensues
rather
-1.4
lymphovascular
buspirone
breakpoint
/EBPb
simvastatin
q22
SULT1A3
habits
Solute
primate
SNRI/
naturally
.74
saline
Five
SRE-1
transfusion
SCD
etoposide
RCK2
IUI
immunomer
simulations
Apoptosis-related
4-fold
IMs
homology-modeled
gene-promoter
enrollment
Sonic
E(2)
MBL
toxin
rs35349697
N-terminal
Sv
l
heat
spinosad
multivariate
oxygenase-1
Y621L
syndromes
preferred
CL4
.57
CCKBR
Levels
OATP
members
NZW
phosphatase
last
luminal
Pharmacokinetic
recommended
LTD
/low-fat
helicase
Variability
rate-limiting
catecholamine
GCKR
BMI
0.836
Cho
hydroxyurea
MEK1(E203K
short
hydrolytic
unlikely
wt
Oxa
PAH
LPS
childhood-onset
check
exploratory
Cumulatively
moderate
25-OH
NR1I1
3A5
melanomas
RDEA119
C-type
polarizing
anaplerotic
Preventive
420
profoundly
1.01
TRb
multiple-dose
maintained
bAt
CCA
Arg205Cys
PD-0332991
Further
Pharmaceuticals
program
single-centre
-transferase-omega
modulating
inconsistencies
Gastric
double-strand
cholinesterase
pleomorphism
MAO-B
post-operative
B-RAF
module
bacterial
177
crucial
600-mg
Functional
dasatinib
moderated
-scanning
presently
13-diacetate
D-serine
.01
0.005
Southeast
blocks
infarct
done
down
LS
above
55.2
6-38
Ab
subepithelial
3.517
naringenin
diffuse
titers
4-aminopyridine
E-cadherin
421CC
CUDC-101
Val30Met
survivin
b-catenin
5-FC
acetaldehyde
N-cadherin
V71I
rs165599
biomarkers
mutation-negative
227.8
specification
regarded
G143E
research
neoadjunctively
GCTATA
genetic-potentiated
TTX
currents
PP(i)
MC1R
ethnicities
non-selective
T-
Abacavir
MATERIALS
mortality
generates
withstand
characteristic
CDK1
mefloquine
traditional
efficient
aberrant
consumes
mercury
5-
intragastric
correction
0.010
location
LIPC
247
contribution
7.5
future
point-mutated
targeting
polyphenol
Dose
deferoxamine
sertraline
equilibrative
25.1
prefrontal
bCD
reasonable
0.60
Modelling
vasospasm
Green
II-
oxypurinol
mitotoxic
Triallelic
Similar
environments
9-benzyl-8-hydroxy-2-(2-methoxyethoxy)adenine
busulfan
linkage
fracture
MMR
bipolar
.2
deficit
rs11085735
RU-24969
high-level
time-related
(S)-3,5-dihydroxyphenylglycine
elective
Patient
Month
transporting
late-onset
percentages
1.11
All
remains
contributions
-3.31
altering
2B6
E2-induced
dichotomized
FBAT
210
T_T
Crizotinib
vulnerability
distinguish
offered
too
PON1
-835
computer-assisted
Prevention
carnitine
They
radioactive
C3
blot
0.063
milbemycin
smaller
-activating
quality-adjusted
A1
minimal
CES2
dogma
chronically
curcumin
HSC-2
Met233Ile
permutation
curative
focus
HRAS
PVN
-mutations
cautiously
CRAd
saquinavir
mmol/L
HEL
Gly16Gln27Thr164
co-administration
resonance
ERN1
preoperatively
transiently
1.14-2
necrosis
5-oxime
lineage
PEI
cost
Primary
PDGF-R
0.35
perception
Cycloheximide
magnetic
C-MYC
20.0
min
Smad2
small-molecule
irradiated
BCR
vinblastine
Acetaminophen
c-Kit
C>G
coordination
MOR-1
monophosphate
subclone
Expression
1.4-fold
helped
contains
POG1
backcrossings
HC/LF
Examining
Asp(9)Asn
R/R
Arg555Trp
KCNA5
Female
stomach
encephalopathy
restricted
methiodide
condition
H1-antihistamine
rs4680
residues
estrone
tolerable
OUTCOME
NRXN3
Val257Met
bladder
Ser10Ser
Evaluation
ERalpha
peripherally
hsCRP
ng/ml
HTRA1
Sulindac
hepcidin
lipoprotein-
cooperate
phosphorus
Knockout
A1298C
87
antibodies
CCT5
p25
RO4987655
[MMA(V)
78
Kyushu
SQSTM1
.05
gamma-carboxyglutamic
cuff
intraindividual
PGR
interferes
MRP1
pneumoniae
MAbs
design
subjective
6.2
leucine
ENPP1
anteroventral
rs1076562
1.5-fold
TCF1
82
demonstrates
trioxide
pramipexole
olaparib
A1/A2
-Mutant
SNAI1
2C
Asthma
First
CBZ-diol
CIMP-positive
RGS2
Leukaemia
147
Kainic
Th1
SNAI3
Cu/ZnSOD
Fgl1
TO
montelukast
lipids
adenoma
cardiomyopathy
SU11274
eradication
57:01
Nicotine
YAC-1
testicular
recall
marrow
HDAC6
inhalation
IU/L
positively
okadaic
HTPR
integrin
Ala
accumbal
respiration
post-transplant
virtually
endemic
defence
ACTH
monitoring
tricyclic
additionally
Raf
gammaH2AX
intact
great
6.5
manipulation
b2-receptor
Env
firstly
DCK
T-lymphocytes
outpatient
Lansoprazole
AhR
catalytic
drinkers
prophylactic
characterize
dimethyl
cysteamine
94
Toll-like
Kv1.5
performing
Heterozygous
Targeting
-hypersensitive
-Induced
analgesia
GFP
faster
evident
HT-29
GSTs
Tac-QD
follow
/SN
G15631T
low-fat
novo
Cooperative
264.7
antagonistic
EIACs
produces
favourable
hypersomnia
HCV-1
0.016
MDA-MB-231
Bt2
personalized
Preliminary
pulmonologists
beta-hydroxylase
monocytes
mid-digital
CL
PC-BSA
ages
analogous
CDDP
huntingtin
EC
needs
.95
.023
Mediterranean
governed
basal-like
myelodysplasia
-deficiency
CG
differential
Hsp90alpha
flushing
Drug
Associated
2.371
Abl
rs671
AWS
elevate
dose-corrected
TKI-na
rs2228576
polyneuropathy
leucocyte
TTR
up
codon751
dose-normalized
48h
Rad51
hypertension
knock-out
validation
Leukemia
autonomic
developing
metabolize
Ile160Thr
-evoked
remarkably
81
Recently
gonadotropin
IM3829
example
geographic
Regarding
presentation
A156V
IOR/OS-1
RARa
O6-benzylguanine
DEX
0.94-1
158/108
47-year-old
Peg-rIFNa-2a
folinic
truncated
thienopyridines
polyphenolic
diagnosed
explored
-.234
IL18
hydroxylase-immunoreactive
NAD(P)H
subtype-specific
0.112
heritable
disappearance
NSHL
0054
1.269
ml/mg/kg
ng.h
distinguished
MDMA
rabeprazole
antioxidants
GALR1
Asp299Gly
limitations
Carbohydrate
relapse-free
pathological
albumin
L/L
relapsed
-485C>T
earlier
SCFAs
m
Two
-wildtypes
C-65
isoflavone
methylphenidate
Possible
substantially
probability
dismutase
I141M
Y1
+24
genetically-determined
pills
15-PGDH
PARP
PEW
Egfr
Lyon
ht1
rs4925
40.7
ameliorate
rs1126647
resting
haemolytic
event-free
hippocampus-dependent
GABRG1
Jordanians
Novartis
affective
8-oxoGua
comparisons
3.5
examining
centrally
bilayers
15-fold
ABCB2
Fms-like
129SvEv
rs1695
codon
nigrostriatal
Inhibiting
coadministered
cilengitide
planar
highlight
regresses
Huntington's
enhancers
thickness
APP/PS1
airway
mL/min
healthy-volunteer
paper
transcript
G010401
contained
chain
CRH
Arg389
except
47
discontinuation
transmission
translate
protocols
Bucindolol
INTRODUCTION
haploinsufficiency
0.001-0
3.25
N-acetyltransferase
cascade
Normalized
abstinent
-1.0
FK506
Cyclosporine
cell-based
XBP1
Inter-individual
Rats
symptomatology
alpha4beta2
ART
FR-pQBI25
overanticoagulation
33
letrozole
mdr1
synergism
AC0010
-38
IL-1B
sensation
instability
1.61
calcium-sensing
677
MT
stasis
Icotinib
66Met
AIAU
widely
MAIN
Few
prostatic
Saururus
multicentre
genome-wide
PEG-IFN-alpha-2a
appropriate
.0004
signature
retrospective
Gly16Glu27Thr164
randomised
lambda-3
macrophages
ErbB-4
surrogate
288
assessment
releasing
medulloblastoma
opiate
phenotypically
CRHR1
intercalated
addicted
caspase-8
SNP23
gene-environment
progestin
duodenal
definitive
rs9479757
-AT1
butyric
NME1
ring
Comparison
adipose
SKOV-3
860
STAT3
drug-resistance
acitretin
BRCA-2
oligonucleotides
17-Hydroxysteroid
MVA
LDLT
enterocyte
transcription-3
usefulness
Adenosine
Journal
HLA-G010403
nateglinide
18B
carotid
46
hybridization
IHC
switch
Homozygosity
link
periventricular
A.
UDP-glucuronosyltransferase
neural
Ile105Val
/C
biopsies
PC-3
polyphenolics
IPA
hyperthermia
-responsive
1075A/C
cefadroxil
1.11-1
CHD
(CYP)
b-blocker/sympatholytic
184
converting
POPular
GSTO1
F508del
rs156697
apomorphine
establishment
topiramate
IgG2a
VerifyNow
Iressa
Lipoprotein
MspI
plasmatic
IgG1
0.045
immunized
parameter
p450
phenobarbital
SN-38G
initiated
deep
black
ARE1
taxol
12-year-old
RAD51
inductive
monomethylarsonous
raclopride
tolerability
range
2006
three-locus
dorsolateral
nephrotic
6G-->T
protruded
Several
circadian
WHI-P131
assays
urine
Screening
CHOP
commercially-available
516TT
aliphatic
(HLA)-B
Asians
rs4653436
implicit
adiponectin
acarbose
Hydrochlorothiazide
Needle
FEV
wildtype
Twenty-seven
Adjusted
engineered
metastasis
predicted
lithospermate
atypia
closed
element
GSTA1
M253T
BI-TK
DSF
rGH
why
extreme
empty
rs9263726
measuring
aggregometry
sulphone
APOC3
percentage
CD80
IVS12-5676A>G
Gly16Arg
0.534
rash
22
/ARE
apply
intrathecal
+8.6
UDP-glucoronosyltransferase
assessing
5-HT3
compound
reach
SLC6A12
changed
2.31
APL
4.33
epigallocatechin-gallate
initiation
5-HTR2A
ADP
ganciclovir
boost
calretinin
sensitizes
transfecting
conduct
preprodynorphin
Vinca
afforded
472,200
automatically
psychiatric
significance
features
subscale
repeats
SCARB1
effector
hamsters
metabolisers
Situations
104
Gilotrif
GTPase
-initiating
shRNA
underlying
somatostatin
Before
-oxygenation
Analysis
measurable
39
lenalidomide
modifying
ICER
699G>A
B10
picryl
Thalidomide
Conditional
enters
network
cooperative
comprising
SNP11646
IVS4+76G>A
Cocaine
lethally
WNT
p.I359L
A549
ACS
1.22-6
Colorectal
Xenopus
Male-specific
DSBs
OGG1
Kirsten
raltitrexed
caudate/nucleus
384
hyperhomocysteinemia
simultaneously
141
GABABR1
5-fluorouracil-5-FUDR
CA
elicit
rs9606186
IL8
excitingly
homeostasis
desensitizes
worldwide
glomerulosclerosis
brushing
muscular
spliced
0.314
abrogates
unaffected
mutagenic
woman
transducer
extrusion
sufficient
source
5-HT4
post-PCI
IPPase
T790M
ng/mL
Random
5-(arenethynyl)
5FU
power
emphasizing
L.
Simultaneously
phosphodiesterase
islands
bud
lineages
H63D
TDL
Protective
mg/kg/h
metabolically
MBP
Younger
nervous
facilitated
PCOS
lopinavir
371.9
responsiveness
witnessed
Lymphoma
sarcoma
social
correlating
non-hematologic
replication
occasional
-514
well-being
disadvantaged
naltrexone
idarubicin
3-kinase-dependent
3-11-fold
-H
putative
23S
TRAIL
K562/A02
head
Ecstasy
NCT00352014
viremia
1.05
profound
-Microglobulinuria
maculopapular
0017
-1639G/A
175
amygdala
DSG
C77G
neocortical
adhesion
yeast
SLCO1B3
ALT1
conjugated
yang
rs737865
laevis
elderly
uterus
ELK1
Identifies
element-1
Serotonin
F617L
-agonists
anti-HBe
cryptotanshinone
Immunohistochemical
stimulation-resistant
IFNa-2
CYP7A1
mitogen-activated
.5
corrected
kinase-9
Caspase-3
hyperabsorption
variabilities
prevailing
relatively
1.0-7
alelle
0.93-1
PRIMA-1
intake
absolute
-455G/A
GABRE
Ser358
post
differentiating
VRX-480773
revolutionized
U0126
July
Trastuzumab
-haplodeficient
ERCC5
41
Thr449Ile
silencing
degrades
statin
translated
Program
66
dose-response
Scr
324
SNAI2
inv
WRN
stavudine
reabsorption
codes
CXCR4
F624
Seven
SLC19A1
hypoglycaemic
10.4
m-CPP
biopsy
/T
Altogether
96
reverses
clearly
liver-specific
Childhood
methoxsalen
renin-angiotensin
F2
phorbol
NVALT
+25
N-methyl-D-aspartate
rs2619538
-linked
11.4
raltegravir
Proenkephalin
H4
Paraffin
00
Logistic
D123G
Nexavar
UGT2B15
(-)-epigallocatechin-3-gallate
RATIONALE
rs1570360
/5-Fu
responds
hyperacetylation
regulator
FRA
c-erbB-2
-LPR
triheptanoin
leucovorin
ligand-independent
Native
hyperplasia
BPRS
CNI-
2.2
ipsilaterally
medium
forced
ERK
DM1
NOS2
NRTIs
HN31
mAb
accuracy
blasts
intertwined
Neuroscience
vector
fluvastatin
Fifty-two
deficient
0.20
rs3745274
promyelocytic
ortholog
insight
hypothyroid
rs4795893
untreated
rs1360780
radiosensitize
5.00
-399A
p.Glu545Lys
bcr1
facets
COX2
rearranged
fexofenadine
nonsignificant
MnCl(2)
rs4149013
http://clinicalTrials.gov/
fewer
real-world
tranylcypromine
HoxB4
VEGF-A
valuable
hypoxanthine
observation
5-aza-2'-deoxycytidine
(IL)-28B
1494C>
Viruses
208
macrocytosis
highlights
NOS2A
diol
AKR-501
CYP2A8
determination
killed
corticotropin
organization
11C
HPLC
0.054
pharmacoepigenetic
rs1042714
Modulation
apnoea
59
units
CYP83A1
CETP
inter-individual
T939C
MIA2
FA-D2
adenoviral
Consortium
motor
0.603
anti-inflammatory
e
caspase3
Tac
F617
generalize
p.Asp260fs
define
K562
N/S
His611Arg
FKBP4
inactivation
36
beta1-AR
0.369
amodiaquine
retinoid
thrombocytopenia
catalysis
3-week
embryonic
soyabean
RESISTANCE
Need
North
CML
2.53
MAOA
progesterone
potency
arcuate
suxamethonium
Luciferase
FokI
GABAB
mt-
mitochondria
multi-drug
rs1051266
implicated
16HBE14o
sex-linked
rs2740574
Canadian
rs5376
considerations
Insulin
LDH
GSTpi
LTP
venlafaxine
down-regulated
CFH
56
chronopharmacokinetics
recurrences
+14.3
selumetinib
2011
SYK
Periareolar
opposing
ABCC10
nominally
182
humanized
hair
single-arm
pombe
seven
Roscovitine
copolymers
disequilibrium
R1881
evolution
quinapril
stiffness
CD86
LNCaP
FOLFOX
A1/A1
morphological
UGT
aurora
Irreversible
T102C
radiosensitizer
participates
Phenotypic
rs29230
NNRTI
besides
BAFs
allele-restricted
involving
slightly
discussed
synonymous
Transforming
heterogeneity
Taxotere
100-240
TAS2R16
Maxdrinks
CCl(4)
-infected
Alleles
A2143G
innately
3-fold
degeneration
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
endoxifen
nonlinear
NAA
-controlled
0024
identical
Mozambique
94C>A
C6
aminoglycoside
requiring
mesoderm
0.264
/Met
PMs
54
newly
neuroprotective
worsen
event-related
probucol
olanzapine
Sult2a1
hearing
Gsta2
HCH
lumefantrine
responding
prothrombotic
Bag-1
norclozapine
Conjugation
manganese
Hippel-Lindau
G/A
GSTO2
SDS
prostratin
C-sweat
bearing
behaviors
29
43
C-G
stress-induced
97
sibutramine
phosphorylcholine
engraftment
concentration-dependent
deposits
intensive
tolerated
AC
1.89
11q
nonphosphorylated
silibinin
spindle
vasodilation
fibroblasts
Inhibits
YKT6
SkM1
L/S
holds
Therapeutic
.03
71
isogenic
STZ
hence
antioxidative
cyclophosphamid
remarkable
routes
vera
WM
3.07-65
0.709
G0105N
Inhibitors
elevates
Analogously
extends
aldosterone
transport
warrants
agonists
hypersensitive
convergent
GAD67-GFP-expressing
EMs
medial
quantitative
Withdrawal
-3435CC
Jews
predispose
-LI
Du145
hemizygous
AOX1
MAF
AZD1152
Nebivolol
hENT1
western
tegaserod
low-activity
clonidine
GATA4
SM360320
NPY1R
Slo2.2
Inventory
TAPBP
C1236T
indicators
sulfhydryl
codon23
mitosis
quetiapine
course
T1974C
250G/A
PCT
minutes
pindolol
12.57
tpj
Differences
sinthase
MFG-E8
prednisolone
PML
Capecitabine
giving
Bupropion
HLA
Thr260Arg
5'-hydroxy
counterparts
promotes
2.95
Y181I
histological
0.046
fatalities
Genotyping
mizoribine
dopa
prednisone
SNPSpD
381.6
0.508
GST-P1
Gly389Gly
alpha-thalassaemic
green
cooperates
Histone
beta2-AR
capability
Thal
enrolment
42
glycosylated
MCJ
kinase-internal
placental
1.4
PTC
direction
Arg399Gln
PASMC
RAW
Cr
RAS-
1173T/C
concentration/dose
nano-imaging
Oncology
encode
-1.6
87.5
IkappaBalpha
haplotypic
nanoparticles
A-241G
rs17862325
decisive
oxidation
rs121912777
antiepileptic
abrogators
C-to-T
homologue
starting
face
521TT
INRs
prodynorphin
cycles
ranging
lymphoblastic
anticonvulsants
downregulation
rs12714145
effectively
analog
Pooled
fear
apoptotic
circulation
Taking
comorbidities
ADIPOQ
unique
TGF-beta
atypical
anthracyclines
miR-122
D314A
HCC-1937
dibutyryl
CCR3
NFATc4
mono
enterocytes
kb
cyclin
S107
mdx
0101
Pak
practice
enzyme-inducing
.90
multi-kinase
CB1-R
DdeI
rectal
crystal
HepG2
isoniazid
GUT-70
GENDEP
bilaterally
acetylation
und
cervical
rs1059288
conditional
c.421C>A
islet
c-kit
rs6943555
CAN
limits
schizophreniform
EGP-2
F227L
ADAL
ameliorates
interferon-alpha
PI3K
CF
18years
30.93
pertuzumab
-acetyltransferase
almost
dl-PFC
ABL
PTEN
-.212
crisis
infants
chemokine
Maprotiline
pSTAT5
transient
Asn(453)Ser
FcyRIIIa
Doses
underanticoagulation
equally
MARCKS
malondialdehyde
CRT
4-week
RyR2
decrement
colitis
doxifluridine
threshold
controversial
co-administered
littermates
1173
trough
G12D
lowest
PET
Instead
traits
Factor
HAGE
PI(4,5)P2
muscimol
possession
immunoreactivity
enrichment
POMC
rs3957357
PCI
procarcinogens
hypotheses
etiology
unfavourable
HER-2/neu
overexpressed
Ranbp2
cohorts
HLA-DR
0.023
CHC-I
-for
88
Twenty-four
Thiopurines
intolerance
Mutated
6.0
intestine
S326C
kainic
1.52
carbohydrate
contraceptive
P26R
42.9
157
up-regulating
hypoxia
L4-L6
carisoprodol
+17.1
10.2
KCl
mg/kg/d
15-pS
1069
Overcoming
Wogonin
demethylation
endothelium
controlling
0.018
53
MBC
zif/268
521TC
Current
0.028
DU-145
E+P
mug
Itraconazole
hepatocyte
TG/TC
International
p-
0.002
sweat
Functionalized
proteasome
a-2
contributing
guide
peroxide
definite
feature
problems
SCNN1A
JBCRN
ITF2357
intramuscular
candidates
FKBP5
521
A1166C
.0005
PVP
template
solvents
experiences
TYMP
GRIN2A
S-1
Recurrence
significiantly
AMD
M204V
rs1128503
remission
chinensis
CTL
mg/day
STMN1
creatine
235T
22,
BRCA2
0.82
G-Rg1
PDD
omega1
transaminase
interferon-free
CMI
alpha-globin
-all
Whereas
Detection
p.Glu542Lys
NRAS
Cyp3a5
0.12
Rare
Veliparib
immunocompromised
reliable
Enzyme
PS
random-effects
Merieux
PROC
Tri-Phosphate
ARRY-142866
blockage
propionate
phosphatidylcholine
7.3
antigenicity
ChD1
JTC801
R296C
myocyte
phenacetin
prevent
subnuclei
Toxic
orally-active
-Related
Single-nucleotide
donor
0.628
0425
close
4-OH-TAM
0.88
proteinuria
expectancy
advance
ACHN
Pdyn
279
alteration
microsatellite
immediately
421
homozygosity
forkhead-associated
0.003
emilin/multimerin
LPS-induced
antagonism
view
conducted
promote
80
Receptor
DFS
Newly
Asn334Ser
Transplantation
Institut
similarly
myocytes
thought
damages
paraventricular
long-chain
Discovery
PC
5-lipoxygenase
ASMko
reasons
upfront
substantia
rs4952
RB1
Gene
Importantly
-1.2
La/g
costimulatory
nitrosamine
swelling
exerts
drinks
LXR
1.6-fold
augmentation
C.
counts
food
differentiates
CD55
transmittance
well-characterized
ABCA1
involve
remaining
trametinib
often
demographic
score
relationships
Hsp90beta
procured
16.23
intoxication
Low
H-2
care
glucosinolates
supra-brainstem
Successful
incentive
temperament
reversible
lipoteichoic
triiodothyronine
quinazoline
0001
G48V
base
females-despite
Cln
high-activity
CAS
AMP
chick
/S/A
across
Fe
strongest
Pharmacogenetic
anthropometrics
/RARa
5843-6276
D2-like
driver
variables
elicited
regarding
Y414C
cooperatively
self-infusion
delimit
interleukin-3
Y621
consequently
N-oleoylethanolamine
dysregulation
problematic
zygotes
HTR1B
abundance
Higher
Interactions
GCK
1C
biotherapy
mitogen
AGT
rs2231142
polluted
FLG
Ezetimibe
CASE
slight
MAPK
catabolic
regard
BRCA-1
AZD9291
abated
routinely
acquisition
eliminate
fasting
G2/M
Ala-->Val
840-mg
Pregnancy
recorded
NTS
mg/kg/2
5.2
FTND
vegetable
TaqIA
mimics
pharmacogenomics
1.31-4
2016
Nyholt
booster
CRF
commissural
Despite
AVT
cobimetinib
ABCC4
.22
0.017
As
CYP19
nearly
exons
achieved
Fine
beta3
taste
oridonin
causes
Intercellular
Western
oxides
rs1870377
g.-1639G-->A
solution
Dabrafenib
toxicities
isolated
Considering
Folate
Bcl-X(L)
pro-drug
interventions
Genomewide
domain-like
exact
transcripts
desipramine
Confirmation
-118
1.47-3
GNAO1
-possibly
alfa
third
Afatinib
arsenate
taking
FAS
addictive
physiological
Angptl3
4'-hydroxylation
thalidomide
CDCA
Phenytoin
STAT
blotting
Vimentin
leukemias
VPA
ARMS2
hematological
mineral
2677G>T
estrone-3-sulfate
1976C>T
Selectively
positive/
Saos-2
favor
core
1,647
aetiological
c.2846A>T
s/s-allele
zinc
chose
40-50
Women
therapy-pretreated
CSNK1E
415-426
non-expressors
tissue-binding
ablation
tBHQ
rs2071888
rs2305948
modification
0.16
alpha4
shortened
hemodialysis
GC
rs16147
liposomes
recipient
confounders
Ala-
3.8
neuropathic
non-expressers
alpha-hydroxylation
contributory
generations
R406
instrument
neck
I50V
interference
GST-M1
epicutaneous
/SHOP
Participants
RE-challenge
steps
chemoprevention
P446L
0.511
C1-Like
region-Abelson
D30N
retina
copolymer
ECOG
3-hydroxy-3-methylglutaryl-coenzyme
PAHs
ER-alpha
transfected
muraglitazar
Celecoxib
detrimental
entities
ceramide
intron
CD34
-to
Thirteen
Differential
doubled
rs13273672
speculated
narrow
C3-C6
regulating
playing
SFRS3
c.2677G>T/A
complexed
testis
5-HT(2C
disrupted
reinstating
3.182
rs2115819
copy
(-)-epigallocatechin
capsaicin
helpful
knockouts
replacement
rs13273442
end
Significant
c.444
-158
N86/184F/D1246
SR
synthesis
aims
HapC
Prediction
reflect
gender-matched
quaternary
up-regulation
projected
GP2
ligand-binding
Rat
repression
SRNS
sumatriptan
cues
ILD
Because
pCAL-
HTR3A
measurements
LOGIK1004A
endometrium
Egyptian
1.101
16Gln27Thr164
mGluR
become
neutropenia
pCR
PPARa
supraventricular
Presence
presents
low-density
AML
difficulties
CH4987655
Multivariate
-embedded
5,10-methylene-tetrahydrofolate
5-fluorocytosine
rs699664
publication
Experimental
mineralocorticoid
ribonucleotide
Ile(462)Val
Small-molecule
cytogenetics
laboratories
pathogenic
pLXRN-4SRE-fPA
86Y/Y184/1246Y
scans
Mitochondrial
GZD824
Cell
Overexpression
personalizing
SrCl2
Onartuzumab
dose-dependently
p-aminobenzoic
0.0001
Immunoglobulin
over
GAA
sirtinol
fragment
T-T-T-T-G
.001
AIDS
g.15582C>T
(V600
1-month
hedgehog
Elucidation
gain-of-function
Gly389Arg
exon-skipping
3.6
optimized
Research
BCSS
subgroups
methadone
0.07
001
entacapone
CCl4
HH
-0.54
3.55
ALDH-2/2
12,
another
p50
understand
2'-O-galloylhyperin
Pharmacokinetics
TLR
Single-Nucleotide
throughout
-2
poor-risk
WT1
samples
-4
semiquantitative
-9
component
0.368
NR2B
ease
-IFN
-2.73
platinums
MCP-1
namely
management
Russian
lovastatin
AIA
IL-1alpha
unilateral
PDGFR
7q
2-fold
autocrine/paracrine
blast
recruitment
-amplified
undergone
calcineurin
Roles
AZ
HLA-DQ
Total
radicicol
Dukes
secretory
impairment
0.041
comorbid
haplotype-specific
suppressive
218
4a-
222
NIH3T3
cycling
strains
self-reported
MATE1
follicular
fluid
PHSF
816
GT
VH1
AF9
A121N
surgical
antiestrogenic
20q
Type
17-allylamino-demethoxygeldanamycin
1.7
generated
A107N
converts
ChS1
poisoning
2/14
adenocarcinomas
abortion
Crohn's
3TC
rtA
apart
389Gly
xenobiotics
UGT1A8
domain-containing
modified
technological
cell-specific
delivered
4b-hydroxycholesterol
Val125Ile
XRE
red
temperature
PK
simply
del322-325
lifetime
lycopene
surprising
degradation
Compared
mCREB
KU19-20
oxygenation
HU
brachytherapy
Rac1
conclusions
detoxification
AUY922
1-34
plasticity
modulation
competitive
Brca2
globulin
ABCC8
rs7687423
hOGG1
approval
granted
clarithromycin
CTx
SGCE
rRNA
May
H.
pylori
schizoaffective
causing
L-DOPA
BTK
Microsomal
mephenytoin
P-450
nNOS
pathology
Combinational
multinational
TLR4
Particularly
lenalidamide
Bruton's
soon
NFkB
Ibruitinib
anti-angiogenesis
Adenovirus-mediated
TNF-b
Prognostic
Ch17CEP
BCL2L12
posaconazole
paradoxical
SWS
osmotic
gallstone
slow-wave
W
periaqueductal
matter
al.
1.16
grey
et
Sastre
60-mmol/L
/drug
withdrawn
mutation-induced
I399
shed
structures
0.19
PANSS
MGP
doi
prostaglandin-endoperoxide
prolonged
SULT1A1
sleep-waking
CR
PDGFR-a
Temsirolimus
episode
hepatotoxic
polygraphically
polymerase-1
-mimicking
exemestane
3'-azido-3'-deoxythymidine
confocal
breaks
undertreated
judged
immunostaining
artificial
-ARE-
ras
orlistat
A116N
profiled
PMH
ARRY-142886
.6
Selumetinib
Turkish
discovered
spermatozoa
many
oPRL
1,25-(OH)2D
Codeine
phosphate
Q172H
fall
piece
Determination
bioactivated
IL-18
eukaryotic
focusing
determinant
binds
retinol
CRBP
MM6
coenzyme
monitored
angiography
AGXT
multifactorial
stenosis
NPC1L1
variance
form
According
pSTAT3
0.45
Mutational
AKT
serves
WY14,643
Evodiamine
amifostine
stresses
dependence-related
adriamycin
HPMA
4.7
electrogenetherapy
Arg389Arg
rs2228093
35-kDa
w10
NAD+
typing
mothers
sappan
Purified
unnoticed
C2
Amazonian
CoA
2.8
1996
saturation
-20
7alpha-hydroxylase
LDL-lowering
G80A
Hydralazine
Genome-based
von
pertinence
114-fold
pediatric
/A
V600
cross-resistance
best
Nigrostriatal
epitope
167
KCNJ11
genotypic
Kidney
Concentrations
later
stimulator
locomotor
nine
France
comprehensive
drive
diallyl
IL-28B
(S)-mephenytoin
rs1800871
FOLFIRI
2/3
IL-10
Bisacurone
rs4646437
knocking
FDA-approved
N236T
roles
tale
786-O
BICD1
apolipoprotein
rs689466
T0901317
ATRA
BalI
stimulation
14.1
TCA-b
biotransformation
Statin
bicalutamide
good
flutamide
impulsivity
Tibetan
worthwhile
GDNF
H3K4me2
Brazilian
lymphocytes
predisposition
URE
A181V/T
Finally
TDF
liability
LoVo
viral-mediated
diazoxon
segmental
BC
focal
AZD7762
MPE
HSS
adding
gene-1
single-agent
Development
rs1260326
NSC
NGFI-B
mostly
valspodar
Ectopic
Hanover
mediates
partner
TaqIB
dystrophy
unnecessary
833
c
defined
concentration/weight-adjusted
far
KIF3A
0.3
muscarinic
.2016.51
b-adrenergic
stimulated
rs1799853
few
living
explanation
subtypes
-intolerant
JUN
KROX-24
FOS
exanthema
S-methyl
ETO
currently
.40
potentiates
0.217
diplotypes
rs1045642
structural
NODAT
Of
SN-38-glucuronide
rs2010963
0.0007
I399C>T
methylene
2.64-fold
2.9
modestly
OEA
10.8
repair
FQI-induced
purine
sulfamoyl
Fourteen
RTQ
.62
CN-AML
galanin
structure
Ratio
conjugates
CEA
VEGFR2
DIO2
VEGFR3
rs307821
CK
C303
Rh
Gln504Lys
ABCG5
/8
sitosterolemia
provocation
Cholestyramine
abrogated
s
rs1024611
rs4586
CCL2
16.6
po
CpG-DNA
distributed
ear
rs2857657
Negative
volume
-orotate
Bryostatin-1
catalyzes
reflecting
prolongs
PSEN1dE985Dbo
poisoned
inside
gene-expressed
Non-Small
fluorescent
name
0.0004-0
AQ
SLC22A2
N-desethylaminodiaquine
establish
INTERVENTIONS
His
Syndrome
ChF1
BM
haplotype-dependent
keratin
de
age-adjusted
.0006
enantiomer
detail
17p
18q
Ton.B210
12p
Neuropeptide
alosetron
quinpirole
-18
Positive
HMGCR
unconjugated
8-week
period
BCRP
IFN-a
arrays
p-fluorofentanyl
TM5
proglucagon
actively
international
BEAS-2B
inducibly
transports
diverse
consistently
structurally
unfavorable
APPswe
spatial
ChU1
Arg-->Gln
two-fold
ISG/
pazopanib
ethinyl
measure
68
indices
5.9-19
SE
within-gene
.I148M
SCAR
FMR1
free
Beck
regressions
UTR
immunomodulation
0-6
(+)
Posaconazole
Selective
Donors
workers
lobe
commenced
0.08
pyrophosphate
catalase
glucose-6-phosphate
aspergillosis
superoxide
peroxidation
GSH
weight-adjusted
Immediate
987
question
Bk2r
rely
T674I
ROS1
120
0.006
neurobiological
J129
APC
mol/l
V
0.393
brazilin
RTV
TPO
offset
triazolam
captopril
intermittent
80G>A
L-AP3
intraseptal
metabolites-had
HSFs
co-injection
supersensitivity
suppressing
L-AP4
sulfinic
SBP
optimal
7.19
Brain
illustrate
ip
Dopamine
adolescent
experimentation
methylated
MOCOS
bound
7-days
DFMO
CB
MS
interfered
0.95
0.75
toxicology
Scientific
3.83
F1
ALOX5
1.75
alkaloids
-16
metabolite
sulphonylurea
6477-6763
rs307826
AZD1152-HQPA
subacute
T69N
sharply
surgery
KCNQ1
RT-PCR
declined
6-month
Variation
MiaPaca2
FPG
benefiting
magnitude
phagocytosis
0.49
infarction
hand
intracerebroventricular
POLG
Aspiration
short-chain
A2A
Haloperidol
pectenotoxin-2
glucosinolate
Capparales
terrestrial
plant
biosynthetic
positivity
phenylpropanoid
Adenoma
alpha-hydroxymetoprolol
C3435Tpolymorphism
nM
EC50
peg-interferon
(HCV)
IIA
DR5
0.50
1000
NAT1
7.2
Arg389Gly-
transglutaminase
non-R/R
CiVDR/PXRa
-adrenergic
nonischemic
Substituting
left
L180M
apoE4
beta-fibrinogen
Ins
rs11076161
322-325
PepT1
SN-38
Diagnostic
UGT2B7
modifier
Del
rs9332127
ICAM-1
follicles
C825T
XPA
amprenavir
nonfunctional
airways
sessions
secondly
modulated
flu
Sequence
cis-platinum
.49
Diplotypes
double
Ad5-
Gly
125I
nutlin-3
CHEK2
HGF
exacerbate
effluxed
rhodamine
graft
L2/L3
lacking
generate
TRAG-3
give
overview
resistance-associated
pPVN
MZ
-inducible
yohimbine
Cholesteryl
MN
0.033
TaqI
Ester
AMH
irrespective
Stromelysin-1
UGT1A6
Ig
SCF
Hepatic
beta(4)
Cu
disulfiram
IBD
1.7-43
therapeutics
MUC1
pegylated-interferon
antialcoholism
TAG
TDBPs
synergistic
breakdown
MOR
access
molecule-1
hypomethylation
co-occurring
Implementation
nonsmall
CDK9
Val(660)Leu
-abuse
composed
Cyclin-dependent
-1639
BSS
brain-derived
high-risk
inherited
Herceptin
RIalpha
identifies
omeprazole
light
-37C-->A
Taq1
donors
-0.31
P1635-
sought
FISH
factor-alpha
rs2619539
IVF
9-month
HRT1B
inter-patient
G>A
INR
proteoliposomes
P-TEFb
Mannose
high-density
751Lys
A-607C
individualization
symptom
rhesus
weak
monkeys
online
attenuated
Omacetaxine
R184S
Network
Compound
enantioselective
antigens
how
pantoprazole
40-250
predilection
Body
cosegregates
rs7089580
limb
-terminally
1236C>T
newborn
ACC
favored
Herpes
considerably
endpoints
8.48
Multitest
chorea
.69
newer
RR
displays
2,000
generally
Clinical
.00003
equal
micromol/L
hydrolase
1.27
I/D
mmol/l
fluoropyrimidine
instead
loop
beyond
Within
manifestations
conventional
Taq1A
NJ
-exposed
polycythemia
entire
-hydroxylase
BH4
key
Major
comparative
NVP
Salmeterol
CPIC
guidelines
dimethylarsinic
requirement
HRQoL
hydrochloride
nonresponders
reinvestigated
-2005
E-3174
/AML
distant
-116C/G
TH
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
SAQUINAVIR
Ph
14.17
sulfide
inducers
infertility
nephrogenous
Poly(ADP-ribose)
autochthonous
analogue
P1635
shunting
susceptible
importantly
Available
CONCLUSIONS/SIGNIFICANCE
hemachromatosis
culture
set
MK-801
parkinsonian
neurotoxin
Parkinson
MPTP
largely
gamma-aminobutyric
3H1
fourfold
Most
selectively
height
22.5
GISTs
G1
usage
I/II
genetics
SiHa
-7
theaflavin
pre-selected
Gln27Glu
complement
MT1-MMP
cost-effective
MMP
Momordica
Pro12Ala
latter
-765G>C
Thiopurine
gamma
kinetic
actions
rs11676382
ICL-induced
ex
1,3-butadiene
400-mg
consolidated
hydrogen
LPV
M41L
Transfer
T181A
HL
biological
multilineage
sulfating
200-mg
glia
mediator
adenomas
removal
DTH
1954
Nutlin-3
MDM2
thermolabile
c.2677G>T
Drd2
cytosine
cats
fluticasone
RGS3
true
SSG
impair
xanthine
arachidonate
KEY
-tranferases
in-depth
discuss
fisetin
4-hydroxy-tamoxifen
promotor
ecstasy
ALAD
retain
launched
postoperative
prescribing
motif]
nongenotoxic
1p/19q
a-glucosidase
-QD
1.39
II/III
planned
Homocysteine
temozolomide
*347_*348insA
pallidal
-1557
localized
tetracycline
RECIST
xanthone
CLL
reducing
hyperglycemia
thiazolidinediones
glucosidase
confirmation
foci
rs1799978
bitter
foundation
corticosteroids
synaptotagmin-1
EA
--
gourd
growing
crozotinib
specificities
5-aminosalicylate
Combining
crystallography
postulated
methimazole
tetrodotoxin
38
sulphamethazine
advances
excluding
valerenic
Trabectedin
biguanides
N40D
generation
rs1799884
type-1
charantia
Consequently
treating
CC-IMT
AM251
CD40L
intima-media
ibudilast
forensic
restrict
Protein
episodes
1.27-2
histocompatibility
PTCA
CyclinB1
PMF
deficiencies
EMID2
relapses
autopsy
0.049
4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one
YM-64227
South
Wy-14643
Drd1
oriental
GnRH
subtype
HTR2A
+7.2
mEH
DSS-induced
xenograft
thromboembolic
+13.8
triple-negative
Y
0.622
SOD
Relative
FIP1L1
infant
PNA-AAV8
p-fluoro
therefore
PNA-AAV6,
rs699947
neuroendocrine
non-carriers
-stimulated
Exposure
consumed
A/A
Ainu-selected
PC12
flow
PNA
mimicked
arms
insertion
wild-types
comparing
butyrate
relations
rIFNa-2b
EGC
about
CPT-11
ESR1
diflunisal
ryanodine
PDLIM5
victims
sudden
Animal
-71
adjust
4218
587
CoCl2
shell
FAK
3145
centromedial
tachyarrhythmia
0.15
Collies
Rapid
MMC
By
0.54
NMR
partially
0.11
ASMF
remodeling
That
Latex
angiogenesis
arterial
GS-9219
deaminase-like
ciclosporin
investigates
intermediate
immunoassays
column
co-segregate
cirrhotic
carcinogenesis
interfere
Glutathione
PegIFN
phosphoribosyltransferase
3.64
site
regulators
time-dependent
gastrointestinal
ALDH1b1
Hepatoprotective
animal
discrete
reinstatement
triggered
47His
1alpha,25-dihydroxyvitamin
interactive
ACh
levamisole
Arg194Trp
spent
converging
FSHR
experiment
His95Arg
Yin
Imiquimod
1.033
rs2630578
5q
123
every
[C-X-C
-3.04
1.25
c.521
S9
2.0
adenocarcinoma
SAHA
Her-2
enrolled
23.6
HTR3B
NSCLCs
delivery
dysfunction
IRENE
Australasian
TCA
chi2
ADH
37/61
47/376
SS
gingival
12.5
VX-770
ectopic
Individual
313
argues
emerged
antithymocyte
translocations
r-ATG
rabbit
FCGR3A
lymphocyte
individually
17-(beta-D-glucuronide
mGlu3
1F
T369I
discovery
person
CYP3a13
decisions
antibiotics
motives
